Klorpromazin etkileşimleri

Avoid administrations of TUDORZA PRESSAIR with other anticholinergic-containing drugs. (Aklidinyum etiketi, İlaç etkileşimleri)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (Amiodaron etiketi, Uyarılar ve önlemler)

…the description of tardive dyskinesia and its clinical detection, please refer to the sections on Information for Patients and ADVERSE REACTIONS . ) Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs and with amoxapine. (Amoksapin etiketi, Uyarılar)

The use of SAPHRIS should be avoided in combination with other drugs known to prolong QTc including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and antibiotics (e.g., gatifloxacin, moxifloxacin). (Asenapin etiketi, Uyarılar ve önlemler)

…phenobarbital, phenytoin Antiarrhythmics Amiodarone (with ritonavir), quinidine (with ritonavir) Antimycobacterials Rifampin Antineoplastics Apalutamide, encorafenib, irinotecan, ivosidenib Antipsychotics Lurasidone (with ritonavir), pimozide Benzodiazepines Orally administered midazolam a , triazolam Ergot Derivatives Dihydroergotamine, ergonovine, ergotamine, methylergonovine… (Atazanavir etiketi, Kontrendikasyonlar)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (Azelastin ve flutikazon etiketi, Uyarılar ve önlemler)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (Azitromisin etiketi, Uyarılar ve önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (Bromokriptin etiketi, Uyarılar ve önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Alpha 1-adrenoreceptor antagonist: alfuzosin Anti-gout: colchicine, in patients with renal and/or hepatic impairment Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Cardiac Disorders: dronedarone, ivabradine, ranolazine Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine Herbal product: St. (Darunavir etiketi, Kontrendikasyonlar)

…antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Anti-gout: colchicine, in patients with renal and/or hepatic impairment Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Cardiac Disorders: dronedarone, ivabradine, ranolazine Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine Herbal product: St. (Darunavir ve kobisistat etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (Difenoksilat ve atropin etiketi, Kontrendikasyonlar)

Usage of MOTOFEN ® in recommended doses is not likely to cause prominent anticholinergic side effects, but MOTOFEN ® should be avoided in patients in whom anticholinergic drugs are contraindicated. (Difenoksin ve atropin etiketi, Uyarılar)

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (Dofetilid etiketi, Uyarılar)

Central nervous system (CNS) depressants: Concurrent use with alcohol or other CNS depressants is not recommended ( 5.1 ) (Doksilamin ve piridoksin etiketi, Uyarılar ve önlemler)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Dötetrabenazin etiketi, Uyarılar ve önlemler)

…Clinical Pharmacology (12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone… (Dronedaron etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products: St. (Elvitegravir, kobisistat, emtrisitabin ve tenofovir etiketi, Kontrendikasyonlar)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (Emtrisitabin, rilpivirin ve tenofovir etiketi, Uyarılar ve önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (Fenelzin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

…6-hour observation, or at additional risk for QT prolongation (e.g., hypokalemia, hypomagnesemia, congenital long-QT syndrome), or on concurrent therapy with QT prolonging drugs with a known risk of torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility. (Fingolimod etiketi, Uyarılar ve önlemler)

Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (Flukonazol etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

…coadministered with the following drugs: Alpha 1-adrenoreceptor antagonist: Alfuzosin Antiarrhythmics: Flecainide (with ritonavir ), propafenone (with ritonavir ) Antimycobacterial: Rifampin Antipsychotic: Lurasidone (with ritonavir ), pimozide Ergot derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine GI motility agent: Cisapride Herbal product: St. (Fosamprenavir etiketi, Kontrendikasyonlar)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (Fosfomisin etiketi, İlaç etkileşimleri)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (Foskarnet etiketi, İlaç etkileşimleri)

• Respiratory Depression: May occur with NEURONTIN when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment. (Gabapentin etiketi, Uyarılar ve önlemler)

• Other Conditions Exacerbated by Anticholinergic Adverse Reactions : Use is not recommended in patients with autonomic neuropathy, hyperthyroidism, cardiac disease, hiatal hernia, etc. (Glikopironyum (glikopirolat) etiketi, Uyarılar ve önlemler)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (Hidroksiklorokin etiketi, Uyarılar ve önlemler)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (Hidroksizin etiketi, Önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Avoid the use of FANAPT in combination with any other drugs that prolong the QT interval [see Warnings and Precautions (5.3) ] . (İloperidon etiketi, İlaç etkileşimleri)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (İpratropium etiketi, İlaç etkileşimleri)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (İvabradin etiketi, Uyarılar ve önlemler)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (Karbamazepin etiketi, İlaç etkileşimleri)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (Karbinoksamin etiketi, Uyarılar ve önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (Ketamin etiketi, İlaç etkileşimleri)

This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (Ketokonazol etiketi, Kontrendikasyonlar)

Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent. (Kinidin etiketi, Kontrendikasyonlar)

Colchicine (in patients with normal renal and hepatic function) Use With Caution Antipsychotics: Pimozide Contraindicated Pimozide: [See Contraindications ( 4.2 )] Quetiapine Lurasidone Quetiapine: Quetiapine is a substrate for CYP3A4, which is inhibited by clarithromycin. (Klaritromisin etiketi, İlaç etkileşimleri)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (Klonidin etiketi, Uyarılar ve önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Proportion of Adult Subjects in Schizophrenia Studies with Weight Gain ≥7% Relative to Baseline Body Weight Weight change CLOZARIL Olanzapine Chlorpromazine N 669 442 155 ≥7% (inclusive) 236 (35%) 203 (46%) 13 (8%) 5.11 Neuroleptic Malignant Syndrome Antipsychotic drugs including CLOZARIL can cause a potentially fatal symptom complex referred to as Neuroleptic… (Klozapin etiketi, Uyarılar ve önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (Levofloksasin etiketi, Uyarılar ve önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (Levosetirizin etiketi, Uyarılar ve önlemler)

…products that are known to prolong the QT interval, including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, antipsychotics (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), or any other drug known to prolong the QT interval (e.g., pentamidine, levomethadyl acetate,… (Loperamid etiketi, Uyarılar)

Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride Hepatitis C direct acting antiviral: elbasvir/grazoprevir HMG-CoA Reductase Inhibitors: lovastatin, simvastatin… (Lopinavir ve ritonavir etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (Lumateperon etiketi, Uyarılar ve önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

• Tardive Dyskinesia (TD), Other Extrapyramidal Symptoms (EPS), and Neuroleptic Malignant Syndrome (NMS) : Avoid concomitant use of other drugs known to cause TD/EPS/NMS and avoid use in patients with Parkinson’s Disease. (Metoklopramid etiketi, Uyarılar ve önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Examples diazepam, alprazolam, alcohol Drugs that Prolong QTc Interval Clinical Impact The concomitant use of other drugs which prolong the QTc interval with REMERON/REMERONSolTab, increase the risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes). (Mirtazapin etiketi, İlaç etkileşimleri)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (Nalmefen etiketi, Uyarılar ve önlemler)

…Antiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidine • Anti-gout: colchicine (in patients with renal and/or hepatic impairment [see Table 2 , Drug Interactions (7.3)] ) • Antipsychotics: lurasidone, pimozide • Benign prostatic hyperplasia agents: silodosin • Cardiovascular agents: eplerenone, ivabradine • Ergot derivatives: dihydroergotamine, ergotamine,… (Nirmatrelvir ve ritonavir etiketi, Kontrendikasyonlar)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (Oksaliplatin etiketi, İlaç etkileşimleri)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (Olopatadin etiketi, Uyarılar ve önlemler)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (Olopatadin ve mometazon etiketi, Uyarılar ve önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (Pazopanib etiketi, İlaç etkileşimleri)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

…in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin, moxifloxacin) [see Drug Interactions (7.1) ] . (Pimavanserin etiketi, Uyarılar ve önlemler)

Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - DRUG INTERACTIONS ). (Pimozid etiketi, Kontrendikasyonlar)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (Pitolisant etiketi, Uyarılar ve önlemler)

In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. (Potasyum sitrat etiketi, Kontrendikasyonlar)

• Respiratory Depression : May occur with LYRICA when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. (Pregabalin etiketi, Uyarılar ve önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (Propafenon etiketi, Uyarılar ve önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

…Concomitant use of clopidogrel and rifampin should be discouraged Increase active metabolite exposure and risk of bleeding Ticagrelor Prevention or Management: Avoid use Decrease exposure Antipsychotics Haloperidol Decrease plasma concentrations by 70% Lurasidone Prevention or Management: Concomitant use is contraindicated (See CONTRAINDICATIONS ) Decrease exposure Oral… (Rifampisin etiketi, İlaç etkileşimleri)

WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (Ritonavir etiketi, Kutulu uyarı)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (Rivastigmin etiketi, İlaç etkileşimleri)

Avoid the concomitant use of drugs known to prolong the QTc interval. (Sertralin etiketi, İlaç etkileşimleri)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (Setirizin etiketi, Uyarılar ve önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (Siprofloksasin etiketi, Uyarılar ve önlemler)

• Central Nervous System Depression Xyrem (sodium oxybate) is a CNS depressant. (Sodyum oksibat etiketi, Kutulu uyarı)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with tetrabenazine tablets and other drugs that reduce dopaminergic transmission [see Drug Interactions (7.6) ]. (Tetrabenazin etiketi, Uyarılar ve önlemler)

…proarrhythmic effects, thioridazine should be reserved for use in the treatment of schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs (see WARNINGS , CONTRAINDICATIONS… (Tioridazin etiketi, Kutulu uyarı)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (Tiotropium etiketi, İlaç etkileşimleri)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

…[Hypertensive Reaction (HR) b or Serotonin Syndrome (SS) c ] Altretamine Use with caution d Orthostatic hypotension e Buspirone Contraindicated a HR Carbamazepine Contraindicated a SS Chlorpromazine Use with caution d Hypotensive effects e Cyclobenzaprine Contraindicated a SS Dextromethorphan Contraindicated a SS; Psychosis, bizarre behavior Dopamine Contraindicated… (Tranilsipromin etiketi, İlaç etkileşimleri)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (Trazodon etiketi, Uyarılar ve önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (Triheksifenidil etiketi, Uyarılar)

Avoid trimethobenzamide hydrochloride capsules in patients receiving other drugs that are likely to cause EPS (e.g. antipsychotics) [see Drug Interactions (7.2) ] . (Trimetobenzamid etiketi, Uyarılar ve önlemler)

Avoid administration of Umeclidinium ELLIPTA with other anticholinergic-containing drugs. (Umeklidinyum etiketi, İlaç etkileşimleri)

Avoid administration of Umeclidinium and Vilanterol ELLIPTA with other anticholinergic-containing drugs. (Umeklidinyum ve vilanterol etiketi, İlaç etkileşimleri)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (Valbenazin etiketi, Uyarılar ve önlemler)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (Vepdegestrant etiketi, Uyarılar ve önlemler)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Therefore, ziprasidone should not be given with: • dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or tacrolimus. (Ziprasidon etiketi, Kontrendikasyonlar)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (Klorpromazin etiketi, Kontrendikasyonlar)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (Allopurinol etiketi, Uyarılar ve önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (Aminofilin etiketi, İlaç etkileşimleri)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (Arformoterol etiketi, İlaç etkileşimleri)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Use with caution in persons who will be exposed to extreme heat, organophosphorus insecticides and in persons receiving atropine or related drugs. (Klorpromazin etiketi, Önlemler)

Use with caution in persons who will be exposed to extreme heat, organophosphorus insecticides and in persons receiving atropine or related drugs. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (Biktegravir, emtrisitabin ve tenofovir alafenamid etiketi, İlaç etkileşimleri)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (Botulinum toksini tip A etiketi, İlaç etkileşimleri)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

Use with CNS depressants may result in an additive or potentiating effect. (Brimonidin etiketi, İlaç etkileşimleri)

Use with CNS depressants may result in an additive or potentiating effect. (Brimonidin ve timolol etiketi, İlaç etkileşimleri)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (Bromfeniramin, psödoefedrin ve dekstrometorfan etiketi, İlaç etkileşimleri)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (Bupivakain etiketi, Uyarılar ve önlemler)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (Bupivakain ve adrenalin etiketi, Uyarılar ve önlemler)

The following conditions can also increase the risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of… (Bupropion etiketi, Uyarılar ve önlemler)

Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (Buspiron etiketi, İlaç etkileşimleri)

Darifenacin extended-release tablets, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as severe constipation, ulcerative colitis, and myasthenia gravis. (Darifenasin etiketi, Uyarılar ve önlemler)

Use with CNS Depressants CORPHENA Oral Solution has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). Use in Activities Requiring Mental Alertness Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc. (Deksklorfeniramin etiketi, Uyarılar)

The intravenous administration of anticholinergic agents (e.g., glycopyrrolate, atropine) should be considered to modify vagal tone. (Deksmedetomidin etiketi, Uyarılar ve önlemler)

Anticholinergic effects of quinidine: Monitor for worsening in myasthenia gravis and other sensitive conditions. (Dekstrometorfan ve kinidin etiketi, Uyarılar ve önlemler)

Because of its CNS depressant effect, chlorpromazine should be used with caution in patients with chronic respiratory disorders such as severe asthma, emphysema and acute respiratory infections, particularly in children (1 to 12 years of age). (Klorpromazin etiketi, Önlemler)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (Desmopressin etiketi, İlaç etkileşimleri)

Drug Interactions Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc). (Difenhidramin etiketi, İlaç etkileşimleri)

The concomitant use of alcohol or other central nervous system depressants may have an additive effect. (Dimenhidrinat etiketi, Uyarılar)

Anticholinergic agents: may affect the gastrointestinal absorption of various drugs; may also increase certain actions or side effects of other anticholinergic drugs (7) (Disikloverin etiketi, İlaç etkileşimleri)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (Doksepin etiketi, Uyarılar ve önlemler)

Observe patients carefully when the dosage of NORTHERA is changed or when concomitant levodopa is reduced abruptly or discontinued, especially if the patient is receiving neuroleptics. (Droksidopa etiketi, Uyarılar ve önlemler)

Because of its CNS depressant effect, chlorpromazine should be used with caution in patients with chronic respiratory disorders such as severe asthma, emphysema and acute respiratory infections, particularly in children (1 to 12 years of age). (Klorpromazin etiketi, Önlemler)

…cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs… (Droperidol etiketi, Uyarılar)

QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between efavirenz and drugs that prolong the QTc interval. (Efavirenz etiketi, İlaç etkileşimleri)

QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between EFV and drugs that prolong the QTc interval. (Efavirenz, lamivudin ve tenofovir etiketi, İlaç etkileşimleri)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (Eribulin etiketi, Uyarılar ve önlemler)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Because of its CNS depressant effect, chlorpromazine should be used with caution in patients with chronic respiratory disorders such as severe asthma, emphysema and acute respiratory infections, particularly in children (1 to 12 years of age). (Klorpromazin etiketi, Önlemler)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

However, it has been reported that chlorpromazine may interfere with the metabolism of phenytoin and thus precipitate phenytoin toxicity. (Klorpromazin etiketi, Önlemler)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Urinary Retention in Adult Patients With Bladder Outlet Obstruction The use of Toviaz, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction, including patients with urinary retention, may result in further urinary retention and kidney injury. (Fesoterodin etiketi, Uyarılar ve önlemler)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (Flibanserin etiketi, Uyarılar ve önlemler)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

Use with caution in combination with other drugs that prolong the QT interval ( 4.2 , 5.11 , 7.7 , 7.8 ) 7.1 Monoamine Oxidase Inhibitors (MAOI) [See Dosage and Administration ( 2.9 , 2.10 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 )] . (Fluoksetin etiketi, İlaç etkileşimleri)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (Fluvoksamin etiketi, İlaç etkileşimleri)

…Antidepressants, QTc Prolonging Drugs Formoterol, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (Formoterol etiketi, İlaç etkileşimleri)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

…medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid… (Glimepirid etiketi, İlaç etkileşimleri)

The following are examples of medication that may reduce the glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease… (Glipizid etiketi, İlaç etkileşimleri)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (Goserelin etiketi, Uyarılar ve önlemler)

Consider the potential for additive sedative effects with CNS depressant drugs. (Guanfasin etiketi, Uyarılar ve önlemler)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Imipramine hydrochloride may enhance the CNS depressant effects of alcohol. (İmipramin etiketi, Uyarılar)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Because of its anticholinergic effects, XEOMIN should be used with caution in patients at risk of developing narrow angle glaucoma. (İnkobotulinumtoksinA etiketi, Uyarılar ve önlemler)

Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (İnsülin aspart etiketi, İlaç etkileşimleri)

Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (İnsülin degludek etiketi, İlaç etkileşimleri)

Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (İnsülin detemir etiketi, İlaç etkileşimleri)

Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents… (İnsülin glarjin etiketi, İlaç etkileşimleri)

Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (İnsülin lispro etiketi, İlaç etkileşimleri)

Caution is, therefore, advised in the co-administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution with other drugs having anticholinergic properties. β-adrenergic agents Caution is advised in the co-administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution and other sympathomimetic agents due to the increased risk… (İpratropium ve salbutamol etiketi, İlaç etkileşimleri)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Antipsychotics, Anxiolytics and Hypnotics Alprazolam Aripiprazole Buspirone Diazepam Haloperidol Midazolam (IV) Quetiapine Ramelteon Risperidone Suvorexant Monitor for adverse reactions. (İtrakonazol etiketi, İlaç etkileşimleri)

Because of its CNS depressant effect, chlorpromazine should be used with caution in patients with chronic respiratory disorders such as severe asthma, emphysema and acute respiratory infections, particularly in children (1 to 12 years of age). (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Because of its CNS depressant effect, chlorpromazine should be used with caution in patients with chronic respiratory disorders such as severe asthma, emphysema and acute respiratory infections, particularly in children (1 to 12 years of age). (Klorpromazin etiketi, Önlemler)

Hyperpyrexia and Confusion Sporadic cases of a symptom complex resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reductions or withdrawal of certain antiparkinsonian agents such as levodopa, carbidopa-levodopa, or carbidopa-levodopa extended release. (Karbidopa etiketi, Uyarılar)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex that resembles neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in dopaminergic therapy. (Karbidopa ve levodopa etiketi, Uyarılar ve önlemler)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (Karbidopa, levodopa ve entakapon etiketi, Uyarılar ve önlemler)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Use with CNS Depressants Clemastine has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). Use in Activities Requiring Mental Alertness Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc. (Klemastin etiketi, Uyarılar)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

TYKERB may prolong the QT interval in some patients. (Lapatinib etiketi, Uyarılar ve önlemler)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex that resembles neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in dopaminergic therapy. (Levodopa etiketi, Uyarılar ve önlemler)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (Lidokain ve adrenalin etiketi, Uyarılar ve önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Because of a possible causal relationship between these events and the concomitant administration of lithium and antipsychotics, patients receiving such combined therapy should be monitored closely for early evidence of neurologic toxicity and treatment discontinued promptly if such signs appear. (Klorpromazin etiketi, Uyarılar)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (Lofeksidin etiketi, Uyarılar ve önlemler)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (Löprolid etiketi, Uyarılar ve önlemler)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (Meflokin etiketi, İlaç etkileşimleri)

• Coadministration of meclizine hydrochloride with other CNS depressants, including alcohol, may result in increased CNS depression ( 7.1 ). (Meklizin etiketi, İlaç etkileşimleri)

Additive Effects Since the effects of meprobamate and alcohol or meprobamate and other CNS depressants or psychotropic drugs may be additive,appropriate caution should be exercised with patients who take more than one of these agents simultaneously. (Meprobamat etiketi, Uyarılar)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (Metirozin etiketi, İlaç etkileşimleri)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (Metronidazol etiketi, İlaç etkileşimleri)

Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (Metskopolamin etiketi, İlaç etkileşimleri)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

There is little or no experience with high exposure, concomitant dosing with other QT-prolonging drugs, or potassium channel variants resulting in a long QT interval. [See Warnings & Precautions ( 5.6 )] To minimize risk, the lowest effective dose should always be used. (Mifepriston etiketi, Uyarılar ve önlemler)

• Urinary Retention in Patients With Bladder Outlet Obstruction and in Patients Taking Muscarinic Antagonist Drugs for Overactive Bladder : Administer with caution in these patients because of risk of urinary retention. (Mirabegron etiketi, Uyarılar ve önlemler)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (Moksifloksasin etiketi, Uyarılar ve önlemler)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (Nalokson etiketi, Uyarılar ve önlemler)

…medications (sulfonylureas and meglitinides) that may cause hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk… (Naltrekson ve bupropion etiketi, Uyarılar ve önlemler)

An anticholinergic agent, (e.g., atropine sulfate or glycopyrrolate) should be administered prior to Neostigmine Methylsulfate Injection administration to lessen the risk of bradycardia [ see Dosage and Administration ( 2.4 ) ]. (Neostigmin etiketi, Uyarılar ve önlemler)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (Nortriptilin etiketi, İlaç etkileşimleri)

Oxybutynin chloride extended-release tablets, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis and intestinal atony. (Oksibutinin etiketi, Uyarılar ve önlemler)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Anticholinergic Drugs Use of anticholinergic drugs after administration of BOTOX may potentiate systemic anticholinergic effects. (OnabotulinumtoksinA etiketi, İlaç etkileşimleri)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (Pasireotid etiketi, İlaç etkileşimleri)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium). (Pilokarpin etiketi, İlaç etkileşimleri)

…medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid… (Pioglitazon ve glimepirid etiketi, İlaç etkileşimleri)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (Piridostigmin etiketi, Uyarılar ve önlemler)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (Ponesimod etiketi, İlaç etkileşimleri)

Concomitant Use with Midazolam : Noxafil can prolong hypnotic/sedative effects. (Posakonazol etiketi, Uyarılar ve önlemler)

Hyperpyrexia and Confusion Although not reported with pramipexole in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction,… (Pramipeksol etiketi, Uyarılar ve önlemler)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (Primakin etiketi, İlaç etkileşimleri)

Anticholinergic drugs administered concurrently with PA may produce additive antivagal effects on A-V nodal conduction, although this is not as well documented for PA as for quinidine. (Prokainamid etiketi, İlaç etkileşimleri)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

The impairment may be amplified by concomitant use of other central-nervous-system depressants such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore such agents should either be eliminated or given in reduced dosage in the presence of promethazine… (Prometazin etiketi, Uyarılar)

The impairment may be amplified by concomitant use of other central-nervous-system depressants such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore such agents should either be eliminated or given in reduced dosage in the presence of promethazine… (Prometazin ve dekstrometorfan etiketi, Uyarılar)

Because of its CNS depressant effect, chlorpromazine should be used with caution in patients with chronic respiratory disorders such as severe asthma, emphysema and acute respiratory infections, particularly in children (1 to 12 years of age). (Klorpromazin etiketi, Önlemler)

Concomitant administration with propranolol results in increased plasma levels of both drugs. (Klorpromazin etiketi, Önlemler)

Protriptyline may enhance the response to alcohol and the effects of barbiturates and other CNS depressants. (Protriptilin etiketi, İlaç etkileşimleri)

Drugs Metabolized by CYP2D6 The exposure to CYP2D6 substrates, such as tricyclic antidepressants and antipsychotics, may be increased during co-administration with ASPRUZYO Sprinkle, and lower doses of these drugs may be required. (Ranolazin etiketi, İlaç etkileşimleri)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (Rasajilin etiketi, Uyarılar ve önlemler)

…doxycycline; Fluoroquinolones (such as ciprofloxacin) Oral Anticoagulants Warfarin Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside… (Rifapentin etiketi, İlaç etkileşimleri)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (Rilpivirin etiketi, Uyarılar ve önlemler)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (Rokuronyum etiketi, Uyarılar ve önlemler)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction of, withdrawal of, or changes in, dopaminergic therapy. (Ropinirol etiketi, Uyarılar ve önlemler)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (Selejilin etiketi, Uyarılar ve önlemler)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Because of its CNS depressant effect, chlorpromazine should be used with caution in patients with chronic respiratory disorders such as severe asthma, emphysema and acute respiratory infections, particularly in children (1 to 12 years of age). (Klorpromazin etiketi, Önlemler)

QT Interval Prolongation and V entricular A rr h ythmia Decreases in serum calcium can also prolong the QT interval, potentially resulting in ventricular arrhythmia. (Sinakalset etiketi, Uyarılar ve önlemler)

CNS Depressants Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents. (Siproheptadin etiketi, Uyarılar)

Avoid use of Citalopram Capsules in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure and patients taking other drugs that prolong the QTc interval. (Sitalopram etiketi, Uyarılar ve önlemler)

• Gastrointestinal and Urinary Disorders : Consider more frequent monitoring during treatment in patients suspected of having intestinal obstruction; patients with pyloric obstruction, patients with impeded urine flow or receiving other anticholinergic drugs. (Skopolamin etiketi, Uyarılar ve önlemler)

Urinary Retention The use of Solifenacin succinate tablets, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction including patients with urinary retention, may result in further urinary retention and kidney injury. (Solifenasin etiketi, Uyarılar ve önlemler)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (Sorafenib etiketi, Uyarılar ve önlemler)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (Sotalol etiketi, İlaç etkileşimleri)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Monitor for hemodynamic changes and administer anticholinergic agents such as atropine if clinically significant bradycardia is observed. (Sugammadeks etiketi, Uyarılar ve önlemler)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib etiketi, İlaç etkileşimleri)

Pretreatment with anticholinergic agents (e.g., atropine) may reduce the occurrence of bradyarrhythmias. (Süksinilkolin etiketi, Uyarılar ve önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (Teofilin etiketi, İlaç etkileşimleri)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

Hyperpyrexia and Confusion: In clinical trials, four cases of a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, and altered consciousness), similar to that reported in association with the rapid dose reduction or withdrawal of other dopaminergic drugs, have been reported in association with… (Tolkapon etiketi, Önlemler)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

…accepted to prolong QT interval include Class 1A (e.g., quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin,… (Toremifen etiketi, İlaç etkileşimleri)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with chlorpromazine and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (Klorpromazin etiketi, Önlemler)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (Triptorelin etiketi, Uyarılar ve önlemler)

Trospium chloride extended-release capsules, like other antimuscarinic agents, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony and myasthenia gravis. (Trospiyum etiketi, Uyarılar ve önlemler)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Urinary Retention : Monitor for urinary retention, especially in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for OAB, in whom the risk of urinary retention may be greater. (Vibegron etiketi, Uyarılar ve önlemler)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Eszopiclone (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased which may Increase the Sedative Effect of Eszopiclone Dose reduction of eszopiclone is recommended. (Vorikonazol etiketi, İlaç etkileşimleri)

Therefore, dosage of anticonvulsants, including barbiturates, should not be reduced if chlorpromazine is started. (Klorpromazin etiketi, Önlemler)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Guanethidine or similarly acting compounds; thyroid medication; alcohol, barbiturates and other CNS depressants; and disulfiram – see WARNINGS section. (Amitriptilin etiketi, İlaç etkileşimleri)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine diminishes the effect of oral anticoagulants. (Klorpromazin etiketi, Önlemler)

Chlorpromazine diminishes the effect of oral anticoagulants. (Klorpromazin etiketi, Önlemler)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Some cases presented with features resembling neuroleptic malignant syndrome. (Atomoksetin etiketi, İlaç etkileşimleri)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

When benztropine mesylate is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly. (Benztropin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine diminishes the effect of oral anticoagulants. (Klorpromazin etiketi, Önlemler)

Chlorpromazine diminishes the effect of oral anticoagulants. (Klorpromazin etiketi, Önlemler)

Chlorpromazine Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning. (Dekstroamfetamin etiketi, İlaç etkileşimleri)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (Doksapram etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Donepezil etiketi, İlaç etkileşimleri)

Chlorpromazine diminishes the effect of oral anticoagulants. (Klorpromazin etiketi, Önlemler)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine diminishes the effect of oral anticoagulants. (Klorpromazin etiketi, Önlemler)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Epoetin alfa etiketi, Uyarılar ve önlemler)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine diminishes the effect of oral anticoagulants. (Klorpromazin etiketi, Önlemler)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamin etiketi, İlaç etkileşimleri)

There have been no definitive drug-drug interaction studies to examine pharmacokinetic or pharmacodynamic interaction with other drugs; however, in humans, granisetron hydrochloride injection has been safely administered with drugs representing benzodiazepines, neuroleptics and anti-ulcer medications commonly prescribed with antiemetic treatments. (Granisetron etiketi, İlaç etkileşimleri)

Chlorpromazine diminishes the effect of oral anticoagulants. (Klorpromazin etiketi, Önlemler)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

NAMZARIC may interfere with anticholinergic medications. (Memantin ve donepezil etiketi, İlaç etkileşimleri)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Some cases presented with features resembling neuroleptic malignant syndrome. (Nefazodon etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (Regüler insülin (insan) etiketi, İlaç etkileşimleri)

Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (Repaglinid etiketi, İlaç etkileşimleri)

Chlorpromazine diminishes the effect of oral anticoagulants. (Klorpromazin etiketi, Önlemler)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly. (Sevimelin etiketi, İlaç etkileşimleri)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Chlorpromazine diminishes the effect of oral anticoagulants. (Klorpromazin etiketi, Önlemler)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use with caution when midazolam or triazolam is concomitantly administered with SUNLENCA 7.4 Drugs without Clinically Significant Interactions with SUNLENCA Based on drug interaction studies conducted with SUNLENCA, no clinically significant drug interactions have been observed with:… (Lenakapavir etiketi, İlaç etkileşimleri)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (Montelukast etiketi, İlaç etkileşimleri)